中国医药：子公司天方药业尼可地尔片拟中选第十一批全国药品集中采购

Core Viewpoint - The company Tianfang Pharmaceutical Co., Ltd. has participated in the 11th national centralized drug procurement bidding, with its Nicorandil tablets expected to be selected, which could positively impact its sales and market share [1] Group 1: Product and Procurement Details - The product in question is Nicorandil tablets, with a specification of 5mg and indicated for angina pectoris [1] - The proposed selection price is 2.59 yuan per box, with each box containing 48 tablets [1] - The procurement cycle is set for three years, from 2026 to December 31, 2028 [1] Group 2: Financial Impact - Tianfang Pharmaceutical's audited revenue for the year 2024 is approximately 52.47 million yuan [1] - The unaudited revenue for the first half of 2025 is about 15.82 million yuan [1] - Winning the bid is expected to help expand product sales scale and improve market share, leading to a positive impact on the company's future performance [1]